|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9757
|
|
pubmed:dateCreated |
2010-12-14
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Bisphosphonates reduce the risk of skeletal events in patients with malignant bone disease, and zoledronic acid has shown potential anticancer effects in preclinical and clinical studies. We aimed to establish whether bisphosphonates can affect clinical outcomes in patients with multiple myeloma.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1474-547X
|
|
pubmed:author |
pubmed-author:AshcroftA JohnAJ,
pubmed-author:BellSue ESE,
pubmed-author:ByrneJenniferJ,
pubmed-author:ChildJ AnthonyJA,
pubmed-author:CocksKimK,
pubmed-author:CookGordonG,
pubmed-author:DaviesFaith EFE,
pubmed-author:DraysonMark TMT,
pubmed-author:FeylerSylviaS,
pubmed-author:GregoryWalter MWM,
pubmed-author:JacksonGraham HGH,
pubmed-author:MorganGareth JGJ,
pubmed-author:National Cancer Research Institute Haematological Oncology Clinical...,
pubmed-author:Navarro-CoyNuriaN,
pubmed-author:OwenRoger GRG,
pubmed-author:RoddieHuwH,
pubmed-author:RossFionaF,
pubmed-author:RudinClaudiusC,
pubmed-author:SzubertAlex JAJ
|
|
pubmed:copyrightInfo |
Copyright © 2010 Elsevier Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
11
|
|
pubmed:volume |
376
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1989-99
|
|
pubmed:dateRevised |
2011-11-4
|
|
pubmed:meshHeading |
pubmed-meshheading:21131037-Adult,
pubmed-meshheading:21131037-Aged,
pubmed-meshheading:21131037-Antineoplastic Agents,
pubmed-meshheading:21131037-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21131037-Bone Density Conservation Agents,
pubmed-meshheading:21131037-Bone Neoplasms,
pubmed-meshheading:21131037-Clodronic Acid,
pubmed-meshheading:21131037-Diphosphonates,
pubmed-meshheading:21131037-Disease-Free Survival,
pubmed-meshheading:21131037-Drug Administration Schedule,
pubmed-meshheading:21131037-Female,
pubmed-meshheading:21131037-Great Britain,
pubmed-meshheading:21131037-Humans,
pubmed-meshheading:21131037-Imidazoles,
pubmed-meshheading:21131037-Infusions, Intravenous,
pubmed-meshheading:21131037-Kaplan-Meier Estimate,
pubmed-meshheading:21131037-Logistic Models,
pubmed-meshheading:21131037-Male,
pubmed-meshheading:21131037-Middle Aged,
pubmed-meshheading:21131037-Multiple Myeloma,
pubmed-meshheading:21131037-Neoplasm Staging,
pubmed-meshheading:21131037-Odds Ratio,
pubmed-meshheading:21131037-Proportional Hazards Models,
pubmed-meshheading:21131037-Research Design,
pubmed-meshheading:21131037-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.
|
|
pubmed:affiliation |
Institute of Cancer Research, Royal Marsden NHS Foundation Trust, London, UK. gareth.morgan@icr.ac.uk
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
